Incyte ruxolitinib data 'a home run, ' says Oppenheimer

theflyonthewall.com

After Incyte reported results from a Phase III study of its ruxolitinib in polycythemia vera, Oppenheimer expects the drug to be approved and generate significant commercial sales. The firm keeps a $75 price target and Outperform rating on the stock.

View Comments (1)